ReviewFrontiers in immunology2026
The epigenetic-immune-microbiome axis in early life: reprogramming the origins and endotypes of pediatric asthma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric asthma is a highly heterogeneous inflammatory syndrome characterized by distinct immune endotypes. The inception of asthma predominantly occurs during the first 1,000 days of life, a critical window of immunological plasticity. Within this critical window, the developing immune system is continuously shaped by dynamic interactions between environmental exposures, the microbiome, and host genetics. Recent advances highlight the epigenetic-immune-microbiome axis as the central mechanism orchestrating these interactions. This review provides a comprehensive synthesis of how prenatal maternal imprinting (including maternal immune activation, nutrition, and psychological stress) and postnatal "second hits" (such as respiratory viral infections and gut-lung microbial dysbiosis)trigger the epigenetic reprogramming of airway epithelial cells and innate/adaptive immune cells. We specifically emphasize the paradigm of "trained immunity" in macrophages and dendritic cells, alongside the hyperactivation of group 2 innate lymphoid cells (ILC2s), as fundamental drivers of asthma pathogenesis. In parallel, we outline the epigenetic and metabolic networks (immunometabolism) that govern T-cell polarization (Th1/Th2/Th17/regulatory T cells) and airway mucosal barrier dysfunction. Finally, we evaluate the translational potential of these multi-omics signatures, discussing how non-invasive approaches like nasal epigenomic profiling may eventually aid in stratifying clinical endotypes and inform the development of future mechanism-based therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.